Objective To investigate the effects of bendamustine(BEN)combined with rituximab+cyclophosphamide,doxorubicin,vincristine,methylprednisolone(R-CHOP)regimen on the efficacy,serum factors,and adverse reactions in patients with diffuse large B-cell lymphoma(DLBCL).Methods A total of 140 DLBCL patients at Handan First Hospi-tal from January 2018 to June 2020 were selected.Using a random number table,they were divided into 2 groups:the control group receiving R-CHOP and the observation group receiving BEN combined with R-CHOP.Their efficacy and safety of the two groups were then compared.Results The objective response rate(ORR)of the observation group was higher than that of the control group[85.71％(60/70)vs.71.43％(50/70),x2=4.242,P＜0.05].Post-treatment,levels of carbohydrate antigen 125(CA125),lactate dehydrogenase(LDH),vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF),and nuclear transcription face-κB p50(NF-κB p50)in the observation group were lower than those in the control group[(18.34±2.75)U/L vs.(22.54±3.11)U/L,(227.16±35.12)U/L vs.(282.71±37.46)U/L,(75.08±10.76)ng/L vs.(81.29±12.41)ng/L,(17.29±1.81)ng/L vs.(19.16±2.07)ng/L,(976.58±104.08)μg/L vs.(1 137.19±197.65)μg/L,P＜0.05].There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P＞0.05).Furthermore,the cumulative survival rate and progression-free survival rate in the observation group were higher than those in the control group(log-rank x2=4.243,3.959,P=0.039,0.047,respectively).Conclusion Combining BEN with R-CHOP improves the short-term and long-term efficacy of DLBCL patients,enhances serum indexes,and ensures safety and effectiveness.
Diffuse large B-cell lymphomaBendamustineR-CHOP protocolCurative effectAdverse reaction
维普
万方数据
